Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PhamAsia News Top Editors' Picks Of 2010

This article was originally published in PharmAsia News

Executive Summary

More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia

You may also be interested in...

China Signals Need For Private Investment To Support Its Healthcare Reforms; Private Insurance Options Likely To Widen

SHANGHAI - China recently lifted a ban on foreign investment in medical institutes to support its $124 billion healthcare reforms and the establishment of wholly foreign-owned hospitals and clinics. The move by the Chinese government is being read as a signal that China may open more of the country's healthcare industry to foreign investment

Patent Cliff Leads Pfizer To Begin Direct Sales To Pharmacies; Aussie Distributors Reeling

SINGAPORE - Pfizer Australia will begin direct sales of its prescription medicines to pharmacies in early 2011, cutting out distributors as part of a global battle to go head-to-head against generic copies of blockbuster drugs like Lipitor that face patent expiry in the coming years

Takeda Shows Signs Of Undergoing Corporate Shift In Decision-making

TOKYO - Takeda has incrementally made a number of organizational announcements in recent months hinting at a shift in the company's outlook to R&D investment and alliance-building in new markets

Related Content

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts